vs
Ginkgo Bioworks Holdings, Inc.（DNA）与GREAT SOUTHERN BANCORP, INC.（GSBC）财务数据对比。点击上方公司名可切换其他公司
GREAT SOUTHERN BANCORP, INC.的季度营收约是Ginkgo Bioworks Holdings, Inc.的1.7倍（$56.4M vs $33.4M），GREAT SOUTHERN BANCORP, INC.同比增速更快（-0.2% vs -23.8%），GREAT SOUTHERN BANCORP, INC.自由现金流更多（$70.1M vs $-47.7M），过去两年GREAT SOUTHERN BANCORP, INC.的营收复合增速更高（4.5% vs -6.2%）
Ginkgo Bioworks Holdings, Inc.是一家2008年由五名麻省理工学院科学家创立的美国生物技术企业，由杰森·凯利掌舵。公司专注于基因工程改造，为其他生物科技企业开发具备工业应用价值的菌株，帮助合作方省去合成生物学设计初期的重复研发成本，号称「生物制造平台企业」，2019年估值就已达42亿美元。
该企业是美国的多元化银行金融机构，总部位于明尼苏达州明尼阿波利斯，在特拉华州注册。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营零售及企业银行业务、投资、抵押贷款等多元金融服务。
DNA vs GSBC — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $33.4M | $56.4M |
| 净利润 | — | $16.3M |
| 毛利率 | — | — |
| 营业利润率 | -211.9% | 34.5% |
| 净利率 | — | 28.9% |
| 营收同比 | -23.8% | -0.2% |
| 净利润同比 | — | 9.1% |
| 每股收益（稀释后） | $-1.41 | $1.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $33.4M | $56.4M | ||
| Q3 25 | $38.8M | $57.8M | ||
| Q2 25 | $49.6M | $59.2M | ||
| Q1 25 | $48.3M | $55.9M | ||
| Q4 24 | $43.8M | $56.5M | ||
| Q3 24 | $89.0M | $55.0M | ||
| Q2 24 | $56.2M | $56.7M | ||
| Q1 24 | $37.9M | $51.6M |
| Q4 25 | — | $16.3M | ||
| Q3 25 | $-80.8M | $17.8M | ||
| Q2 25 | $-60.3M | $19.8M | ||
| Q1 25 | $-91.0M | $17.2M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | $-56.4M | $16.5M | ||
| Q2 24 | $-217.2M | $17.0M | ||
| Q1 24 | $-165.9M | $13.4M |
| Q4 25 | -211.9% | 34.5% | ||
| Q3 25 | -231.8% | 38.2% | ||
| Q2 25 | -132.1% | 41.0% | ||
| Q1 25 | -184.1% | 38.4% | ||
| Q4 24 | -236.3% | 31.8% | ||
| Q3 24 | -62.0% | 36.6% | ||
| Q2 24 | -396.7% | 36.8% | ||
| Q1 24 | -469.1% | 32.1% |
| Q4 25 | — | 28.9% | ||
| Q3 25 | -207.9% | 30.7% | ||
| Q2 25 | -121.6% | 33.4% | ||
| Q1 25 | -188.2% | 30.7% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | -63.3% | 30.0% | ||
| Q2 24 | -386.4% | 30.0% | ||
| Q1 24 | -437.3% | 26.0% |
| Q4 25 | $-1.41 | $1.44 | ||
| Q3 25 | $-1.45 | $1.56 | ||
| Q2 25 | $-1.10 | $1.72 | ||
| Q1 25 | $-1.68 | $1.47 | ||
| Q4 24 | $-1.91 | $1.27 | ||
| Q3 24 | $-1.08 | $1.41 | ||
| Q2 24 | $-4.23 | $1.45 | ||
| Q1 24 | $-3.32 | $1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $422.6M | $189.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $508.6M | $636.1M |
| 总资产 | $1.1B | $5.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $422.6M | $189.6M | ||
| Q3 25 | $495.5M | $196.2M | ||
| Q2 25 | $559.4M | $245.9M | ||
| Q1 25 | $325.3M | $217.2M | ||
| Q4 24 | $561.6M | $195.8M | ||
| Q3 24 | $616.2M | $208.4M | ||
| Q2 24 | $730.4M | $186.5M | ||
| Q1 24 | $840.4M | $171.4M |
| Q4 25 | $508.6M | $636.1M | ||
| Q3 25 | $559.8M | $632.9M | ||
| Q2 25 | $613.0M | $622.4M | ||
| Q1 25 | $647.4M | $613.3M | ||
| Q4 24 | $716.1M | $599.6M | ||
| Q3 24 | $797.9M | $612.1M | ||
| Q2 24 | $833.1M | $568.8M | ||
| Q1 24 | $987.3M | $565.2M |
| Q4 25 | $1.1B | $5.6B | ||
| Q3 25 | $1.2B | $5.7B | ||
| Q2 25 | $1.2B | $5.9B | ||
| Q1 25 | $1.3B | $6.0B | ||
| Q4 24 | $1.4B | $6.0B | ||
| Q3 24 | $1.5B | $6.0B | ||
| Q2 24 | $1.6B | $6.0B | ||
| Q1 24 | $1.6B | $5.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-47.7M | $81.5M |
| 自由现金流经营现金流 - 资本支出 | $-47.7M | $70.1M |
| 自由现金流率自由现金流/营收 | -142.8% | 124.3% |
| 资本支出强度资本支出/营收 | 0.0% | 20.3% |
| 现金转化率经营现金流/净利润 | — | 5.01× |
| 过去12个月自由现金流最近4个季度 | — | $121.9M |
8季度趋势，按日历期对齐
| Q4 25 | $-47.7M | $81.5M | ||
| Q3 25 | $-31.6M | $5.6M | ||
| Q2 25 | $-40.3M | $39.3M | ||
| Q1 25 | $-51.5M | $15.0M | ||
| Q4 24 | $-42.4M | $44.1M | ||
| Q3 24 | $-103.5M | $17.7M | ||
| Q2 24 | $-84.4M | $43.5M | ||
| Q1 24 | $-89.3M | $-26.9M |
| Q4 25 | $-47.7M | $70.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $-40.3M | $34.9M | ||
| Q1 25 | $-59.1M | $13.1M | ||
| Q4 24 | $-56.1M | $39.1M | ||
| Q3 24 | $-118.6M | $16.5M | ||
| Q2 24 | $-111.4M | $42.0M | ||
| Q1 24 | $-96.0M | $-27.7M |
| Q4 25 | -142.8% | 124.3% | ||
| Q3 25 | — | 6.7% | ||
| Q2 25 | -81.2% | 59.0% | ||
| Q1 25 | -122.4% | 23.4% | ||
| Q4 24 | -128.0% | 69.3% | ||
| Q3 24 | -133.2% | 30.1% | ||
| Q2 24 | -198.2% | 74.1% | ||
| Q1 24 | -252.9% | -53.7% |
| Q4 25 | 0.0% | 20.3% | ||
| Q3 25 | 0.0% | 3.0% | ||
| Q2 25 | 0.1% | 7.4% | ||
| Q1 25 | 15.8% | 3.5% | ||
| Q4 24 | 31.3% | 8.7% | ||
| Q3 24 | 16.9% | 2.1% | ||
| Q2 24 | 48.1% | 2.7% | ||
| Q1 24 | 17.7% | 1.6% |
| Q4 25 | — | 5.01× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 1.99× | ||
| Q1 25 | — | 0.87× | ||
| Q4 24 | — | 2.95× | ||
| Q3 24 | — | 1.07× | ||
| Q2 24 | — | 2.56× | ||
| Q1 24 | — | -2.01× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DNA
| Cell Engineering Segment | $26.0M | 78% |
| Other | $7.4M | 22% |
GSBC
暂无分部数据
